Johnson & Johnson announced that the Phase 3 MonumenTAL-3 study demonstrated that TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, significantly improved progression-free survival (up to 81.3%) and overall survival (up to 89.2%) at 24 months in patients with relapsed or refractory multiple myeloma. The study showed a 72% reduction in disease progression or death risk compared to standard treatment. These results mark the first Phase 3 evidence of a GPRC5D bispecific antibody combination's effectiveness earlier in treatment, potentially expanding therapeutic options. Johnson & Johnson is pursuing regulatory approvals to bring this combination to patients globally.
Five established companies—Johnson & Johnson, PepsiCo, Coca-Cola, Exxon Mobil, and Kimberly-Clark—have declared new dividends backed by decades of consistent payout increases. Each company recently reported strong earnings or raised guidance, signali...
Johnson & Johnson's stock reached $270.24, close to its 52-week high of $276.47, following raised full-year guidance and FDA approval of a new robotic surgical system. The company shows strong growth in oncology and immunology, with key products like...
Jim Cramer highlighted a market rotation away from tech and data center stocks toward enterprise software and pharmaceuticals, driven by political opposition to data center construction and bond market volatility. Software companies like ServiceNow, ...
With the 10-Year Treasury yield at 4.74%, dividend stocks must offer durable income. Dividend Aristocrats, companies with 25+ years of dividend increases, remain reliable for retirement income. Coca-Cola, Procter & Gamble, Johnson & Johnson, PepsiCo,...
The FDA has approved IMAAVY (nipocalimab-aahu) for treating warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older, marking the first therapy specifically proven safe and effective for this rare, life-threatening disease. IMAAVY works...
